AstraZeneca’s Lynparza Plus Imfinzi Receives the EC’s Approval to Treat Endometrial Cancer
Shots:
- Following the CHMP’s positive opinion, the EC has approved Imfinzi + CT followed by Lynparza with Imfinzi and Imfinzi alone as a 1L treatment of pMMR & dMMR disease, respectively, based on P-III (DUO-E) study assessing the combination vs CT in patients (n=699) with advanced/recurrent endometrial cancer
- Study showed reduced disease progression or death risk by 43% (mPFS: 15mos. vs 9.7mos.) pMMR disease population and by 58% (mPFS: not reached vs 7mos.) in dMMR disease population. Data was published in Journal of Clinical Oncology
- Further submissions are being reviewed across Japan & other regions for the same. It is approved in the US for dMMR disease
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca’s Lynparza Plus Imfinzi Receives the CHMP’s Positive Opinion for Treating Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.